✦ LIBER ✦

Phase II study of VP 16-213 (etoposide) in metastatic transitional cell urothelial cancer

✍ Scribed by B. A. J. Ponder; R. T. D. Oliver

Publisher: Springer
Year: 1984
Tongue: English
Weight: 227 KB
Volume: 12
Category: Article
ISSN: 0344-5704
DOI: 10.1007/bf00255913

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II study of VP16-213 (Etoposide) i

Phase II study of VP16-213 (Etoposide) in refractory metastatic breast carcinoma

✍ F. C. Schell; H. Y. Yap; G. N. Hortobagyi; B. Issell; L. Esparza 📂 Article 📅 1982 🏛 Springer 🌐 English ⚖ 302 KB

Phase II study of oral VP-16-213 in smal

Phase II study of oral VP-16-213 in small cell lung cancer

✍ Yasaku Matsui; Shunsaku Oshima; Masao Kado; Masahiko Nakayama; Kaoru Shimokata; 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 345 KB 👁 1 views

Phase II trial of VP16-213 in non-small

Phase II trial of VP16-213 in non-small cell lung cancer (NSCLC)

✍ Robert Chapman; Loretta Itri; Richard Gralla; David Kelsen; Ephraim Casper; Robe 📂 Article 📅 1982 🏛 Springer 🌐 English ⚖ 238 KB

Phase II study of mitomycin C, etoposide

Phase II study of mitomycin C, etoposide and vindesine in metastatic stage IV non-small-cell lung cancer

✍ Cesare Gridelli; Rosario Pepe; Sergio Palmeri; Stefano Iacobelli; Maria Gentile; 📂 Article 📅 1991 🏛 Springer 🌐 English ⚖ 315 KB

Phase II study of single-agent etoposide

Phase II study of single-agent etoposide in patients with metastatic squamous-cell carcinoma of the esophagus

✍ Andreas Harstrick; Carsten Bokemeyer; Peter Preusser; Claus Henning Köhne-Wömpne 📂 Article 📅 1992 🏛 Springer 🌐 English ⚖ 215 KB

Phase II trial of vindesine and VP16-213

Phase II trial of vindesine and VP16-213 in the palliation of poor-prognosis patients and elderly patients with small cell lung cancer

✍ Simon G. Allan; Anna Gregor; Michael A. Cornbleet; Robert C. F. Leonard; John F. 📂 Article 📅 1984 🏛 Springer 🌐 English ⚖ 320 KB

Forty-three previously untreated patients, all of whom had poor-prognosis small cell lung cancer and/or were greater than 65 years old, received treatment with vindesine and VP16-213. Thirteen patients had limited disease and 30 extensive disease. Response rates (CR + PR) of 86% (CR 29%) and 66% (CR